This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Ambit Biosciences Corp. (developing kinase inhibitors) has finally completed its initial public offering, netting $60.5mm through the sale of 8mm shares at $8. The company first filed in November 2010 but withdrew in June 2011, and then filed again in February 2013. Earlier this month, Ambit announced that it hoped to sell 4.6mm shares for between $13-15 apiece.
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?